These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30616755)

  • 61. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
    Rivera M; Bander ED; Cisse B
    World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel approaches and mechanisms of immunotherapy for glioblastoma.
    Hegde M; Bielamowicz KJ; Ahmed N
    Discov Med; 2014 Mar; 17(93):145-54. PubMed ID: 24641957
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy.
    Yeo ECF; Brown MP; Gargett T; Ebert LM
    Cells; 2021 Mar; 10(3):. PubMed ID: 33803414
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Overview of cellular immunotherapy for patients with glioblastoma.
    Vauleon E; Avril T; Collet B; Mosser J; Quillien V
    Clin Dev Immunol; 2010; 2010():. PubMed ID: 20953324
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immune Checkpoint Inhibitors in Human Glioma Microenvironment.
    Ghouzlani A; Kandoussi S; Tall M; Reddy KP; Rafii S; Badou A
    Front Immunol; 2021; 12():679425. PubMed ID: 34305910
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular Mechanisms of Treatment Resistance in Glioblastoma.
    Ou A; Yung WKA; Majd N
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396284
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.
    Van Meir EG; Hadjipanayis CG; Norden AD; Shu HK; Wen PY; Olson JJ
    CA Cancer J Clin; 2010; 60(3):166-93. PubMed ID: 20445000
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives.
    Abadi B; Yazdanpanah N; Nokhodchi A; Rezaei N
    Adv Drug Deliv Rev; 2021 Dec; 179():114035. PubMed ID: 34740765
    [TBL] [Abstract][Full Text] [Related]  

  • 71. PTEN Mutations Trigger Resistance to Immunotherapy.
    Cheng F; Eng C
    Trends Mol Med; 2019 Jun; 25(6):461-463. PubMed ID: 30928438
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
    Bair SM; Mato A; Svoboda J
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tumor-Specific T Cell Activation in Malignant Brain Tumors.
    Mohme M; Neidert MC
    Front Immunol; 2020; 11():205. PubMed ID: 32117316
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Our experience with targeted therapy in glioblastoma multiforme].
    Kiss E; Lahm E; Vachaja J; Nagy P; Bazsó P; Fekete Z; Takácsi-Nagy Z; Pápai Z
    Magy Onkol; 2013 Dec; 57(4):264-8. PubMed ID: 24353992
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Myeloid Cells in Glioblastoma Microenvironment.
    De Leo A; Ugolini A; Veglia F
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A novel treatment for glioblastoma: integrin inhibition.
    Chamberlain MC; Cloughsey T; Reardon DA; Wen PY
    Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
    Pombo Antunes AR; Scheyltjens I; Duerinck J; Neyns B; Movahedi K; Van Ginderachter JA
    Elife; 2020 Feb; 9():. PubMed ID: 32014107
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Microglia-Centered Combinatorial Strategies Against Glioblastoma.
    Martins TA; Schmassmann P; Shekarian T; Boulay JL; Ritz MF; Zanganeh S; Vom Berg J; Hutter G
    Front Immunol; 2020; 11():571951. PubMed ID: 33117364
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
    Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
    Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recent advances and future of immunotherapy for glioblastoma.
    Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.